Skip to main content
. 2018 Nov 28;110(1):23–30. doi: 10.1111/cas.13849

Figure 2.

Figure 2

Trend of FDA‐approved targeted inhibitors between 1995 and 2017. The number of FDA‐approved targeted antitumor inhibitors increases dramatically, compared with other antitumor drugs